Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains Focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Axovant Sciences (AXON) PT Lowered to $9 at Evercore ISI
September 26, 2017 12:07 PM EDTEvercore ISI analyst Josh Schimmer lowered his price target on Axovant Sciences (NASDAQ: AXON) to $9.00 (from $30.00) while maintaining an Outperform rating after MINDSET Trial Fails
... MoreAxovant Sciences (AXON) PT Lowered to $19 at JMP Securities
September 26, 2017 11:37 AM EDTJMP Securities lowered its price target on Axovant Sciences (NASDAQ: AXON) to $19.00 (from $36.00) while maintaining a Market Outperform rating.
Analyst Jason Butler cites the ngative MINDSET results. The analyst comments "We have removed all value for intepirdine from our... More
UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to Neutral
September 26, 2017 10:53 AM EDT(Updated - September 26, 2017 11:02 AM EDT)
(updated to add analyst comment)
Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) from Overweight to Neutral with a price target of $9.00 (from $32.00).
Analyst Charles Duncan says the pipeline needs to be rebuild... More
Oppenheimer Downgrades Axovant Sciences (AXON) to Perform
September 26, 2017 10:48 AM EDTOppenheimer downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Perform.
For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.
Shares of Axovant Sciences closed at $24.25 yesterday.
... MoreUPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital Markets
September 26, 2017 9:49 AM EDT(Updated - September 26, 2017 9:52 AM EDT)
(updated to add comments)
Chardan Capital Markets lowered its price target on Axovant Sciences (NASDAQ: AXON) to $3.00 (from $8.00) while maintaining a Sell rating after the company fails to demonstrate statistical significance on either co-primary endpoint (ADAS-Cog and ADCS-ADL) in the phase III MINDSET trial of intepirdine in mild-to-moderate... More
Top five unique options volume: AMAT EFX NKE AXON GE
September 26, 2017 9:46 AM EDTTop five unique options volume: AMAT EFX NKE AXON GE
... MoreBaird Downgrades Axovant Sciences (AXON) to Neutral, $6 PT
September 26, 2017 9:38 AM EDTBaird downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Neutral with a price target of $6.00 (from $29.00) after the failure of the Phase 3 MINDSET study in Alzheimer's.
Analyst Brian Skorney commented, " There may be a reasonable argument to allow thesis drift here, given the... More
Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy Endpoints
September 26, 2017 7:02 AM EDTAxovant Sciences (NASDAQ: AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease (AD) who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), respectively, compared to patients treated with placebo. In the study, intepirdine was... More
